Overexpression of Hexokinase 1 as a poor prognosticator in human colorectal cancer
It has been suggested that hexokinase 1 (HK1) is involved in tumorigenesis. However, the expression dynamics of HK1 and its prognostic significance in human colorectal cancer (CRC) still remain unclear. The aim of the present study was to investigate the expression of HK1 and its prognostic significance in CRC. In this study, immunohistochemical analysis was used to examine the expression dynamics of HK1 in CRC tissues from two independent cohorts. Receiver operating characteristic curve analysis, Kaplan–Meier curves, and Cox regression analysis were utilized to investigate the prognostic significance. Results showed that a high expression of HK1 was observed in 106 of 393 (27.0 %) and 69 of 229 (30.1 %) of CRC in the training cohort and validation cohort, respectively. Further correlation analyses indicated that the increased HK1 expression was strongly correlated with the pN classification and TNM stage. Both cohorts showed a close association between the overexpression of HK1 and poorer overall survival. Importantly, multivariate analysis identified HK1 expression in CRC as an independent prognostic factor. Overexpression of HK1 may act as a significant biomarker of poor prognosis for patients with CRC.
KeywordsColorectal cancer Hexokinase Prognosis Biomarker
Compliance with ethical standards
This study was approved by the IRB of the Sixth Affiliated Hospital and Cancer Center, Sun Yat-sen University.
Conflicts of interest
Declaration of funding interests
This work is supported by the National Natural Science Foundation of China (81400604).
- 20.Oronsky BT, Oronsky N, Fanger GR, Parker CW, Caroen SZ, Lybeck M, et al. Follow the ATP: tumor energy production. A perspective. Anticancer Agents Med Chem. 2014.Google Scholar
- 25.Colombini M. VDAC structure, selectivity, and dynamics. Biochim Biophys Acta. 1818;2012:1457–65.Google Scholar
- 27.Martel C, Wang Z, Brenner C. VDAC phosphorylation, a lipid sensor influencing the cell fate. Mitochondrion. 2014.Google Scholar
- 35.Li H, Zeng J, Shen K. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 2014.Google Scholar